

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **VOLUNTARY ANNOUNCEMENT PROPOSED BID-WINNING RESULTS OF NATIONAL CENTRALISED PROCUREMENT OF PHARMACEUTICALS**

This announcement is made by The United Laboratories International Holdings Limited (the “Company”) on a voluntary basis.

The board of directors of the Company is pleased to announce that, on 26 November 2021, Zhuhai United Laboratories Co., Ltd. (珠海聯邦制藥股份有限公司) and Zhuhai United Laboratories Co., Ltd., Zhongshan Branch (珠海聯邦制藥股份有限公司中山分公司), a wholly-owned subsidiary of the Company, participated in the bidding for the Sixth National Centralised Procurement of Pharmaceuticals (specialising in Insulin) organised by the National Organisation Office for Centralised Procurement of Pharmaceuticals. The insulin products of the Company are expected to win the bidding in this centralized procurement. The relevant information is now disclosed as follows:

#### **Basic Information of the Company’s Proposed Bid-winning Products**

<b>No. of Procurement Group</b>	<b>Name of Procurement Group</b>	<b>Name of Products</b>	<b>Specification and Packaging</b>	<b>Tendering Price (RMB/vial)</b>	<b>Ranking Category*</b>	<b>Basic volume of first year's procurement (vial)</b>
1	Mealttime Insulin	Human Insulin Injection	3ml: 300 units (refilled pen-type)	28.77	A3	598,737
2	Basal Insulin	Protamine Insulin Injection	3ml: 300 units (refilled pen-type)	29.37	A3	230,111
3	Premixed Insulin	Protamine Insulin Mixed Injection (30R/50R)	3ml: 300 units (refilled pen-type)	27.37	B	9,225,570
4	Mealttime Insulin Analogue	Insulin Aspart Injection	3ml: 300 units (refilled pen-type)	41.27	B	149,388
5	Basal Insulin Analogue	Insulin Glargine Injection	3ml: 300 units (refilled pen-type)	66.97	A2	1,726,254
6	Premixed Insulin Analogue	Insulin Aspart 30 Injection	3ml: 300 units (refilled pen-type)	41.27	B	330,610

\*1. The agreed volume for this centralised insulin procurement includes the basic volume and the allocated volume;

2. Basic volume: in the same procurement group, the selected products are divided into three categories according to their rankings, namely categories A, B and C. The selected products in categories A1, A2, A3, B and C will receive 100%, 90%, 85%, 80% and 50% of their first year's procurement demand, respectively, while the products in category D are products that meet the bidding requirements but have not participated in the bidding or have not been selected;
3. Allocated volume: 30% of the first year's procurement demand from the selected products in category C will be allocated to the selected products in category A, and 80% of the first year's procurement demand of the selected products in category D will be allocated to the selected products in categories A and B.

### **The expected impact of the proposed bidding on the Company**

This centralised procurement is the sixth batch of centralized procurement of pharmaceuticals (specialising in insulin) organised by the national government. The procurement products include insulin and insulin analogues in mealtime, basal and premixed groups. The duration of the procurement cycle is two years, and medical institutions will give priority to the selected pharmaceuticals in this centralized procurement and will ensure the agreed procurement volume. The price of the Company's proposed bid-winning products has dropped to a certain extent compared with the original price, but there is the guarantee of the agreed basic procurement volume. At the same time, the Company's bidding products in categories A and B will also receive the allocated volume of the products in categories C and D. The confirmation of winning bids by the Company and the subsequent signing and execution of the procurement agreement will help expand the sales of the above products, increase their market shares in the insulin products market, enhance the Company's brand influence, benefit the diabetic patients and accelerate domestic substitution,. It is also expected to have a positive impact on the Company's future operations and developments.

On behalf of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 29 November 2021

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.